Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
United States
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our US operations at oncopeptides-us.com
Change Language
Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
United States
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our US operations at oncopeptides-us.com
Change Language
On Monday, Oncopeptides’ CEO Sofia Heigis was interviewed by Redeye’s life science analyst Richard Ramanius. The conversation touched on, among other things, the recently announced new rights issue, what the European market for multiple myeloma drugs looks like and status on the ongoing commercialization in Europe.
Watch the interview via this link (requires free membership at Redeye).
